John Arthur
Concepts (337)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Proteomics | 23 | 2019 | 292 | 3.760 |
Why?
| Acute Kidney Injury | 15 | 2024 | 291 | 3.330 |
Why?
| Renal Insufficiency, Chronic | 10 | 2024 | 170 | 2.630 |
Why?
| Glomerulonephritis, Membranous | 6 | 2023 | 27 | 1.710 |
Why?
| Electrophoresis, Gel, Two-Dimensional | 18 | 2010 | 37 | 1.420 |
Why?
| Kidney | 10 | 2020 | 672 | 1.380 |
Why?
| Lupus Nephritis | 5 | 2023 | 17 | 1.070 |
Why?
| Proteinuria | 5 | 2007 | 36 | 1.030 |
Why?
| Kidney Diseases | 3 | 2019 | 211 | 0.880 |
Why?
| Autoantibodies | 3 | 2023 | 114 | 0.830 |
Why?
| Glomerulonephritis | 2 | 2019 | 14 | 0.760 |
Why?
| Proteins | 5 | 2010 | 347 | 0.740 |
Why?
| Kidney Glomerulus | 8 | 2019 | 39 | 0.690 |
Why?
| Proteome | 3 | 2019 | 153 | 0.680 |
Why?
| Uremia | 1 | 2019 | 12 | 0.660 |
Why?
| Ruminococcus | 1 | 2019 | 7 | 0.650 |
Why?
| Starch | 1 | 2019 | 12 | 0.650 |
Why?
| Urea | 1 | 2019 | 77 | 0.640 |
Why?
| Cecum | 1 | 2019 | 59 | 0.640 |
Why?
| Glomerular Filtration Rate | 3 | 2015 | 110 | 0.620 |
Why?
| Predictive Value of Tests | 11 | 2018 | 907 | 0.610 |
Why?
| Bacteria | 2 | 2020 | 219 | 0.610 |
Why?
| Hypertension | 4 | 2020 | 531 | 0.600 |
Why?
| Intestines | 1 | 2019 | 169 | 0.590 |
Why?
| Diabetic Nephropathies | 4 | 2015 | 61 | 0.590 |
Why?
| Humans | 53 | 2024 | 49929 | 0.570 |
Why?
| Prognosis | 9 | 2024 | 1957 | 0.570 |
Why?
| Bacterial Proteins | 2 | 2019 | 372 | 0.570 |
Why?
| Cardiac Surgical Procedures | 3 | 2024 | 304 | 0.560 |
Why?
| Renin-Angiotensin System | 6 | 2021 | 59 | 0.530 |
Why?
| Glomerulosclerosis, Focal Segmental | 3 | 2014 | 13 | 0.490 |
Why?
| Animals | 29 | 2024 | 13100 | 0.480 |
Why?
| Interleukin-18 | 2 | 2015 | 27 | 0.470 |
Why?
| Renal Replacement Therapy | 2 | 2023 | 28 | 0.460 |
Why?
| Disease Progression | 7 | 2020 | 820 | 0.460 |
Why?
| Rats | 14 | 2024 | 3273 | 0.450 |
Why?
| Hyponatremia | 2 | 2011 | 11 | 0.440 |
Why?
| Benzazepines | 2 | 2011 | 19 | 0.440 |
Why?
| Membrane Glycoproteins | 2 | 2015 | 244 | 0.430 |
Why?
| Male | 33 | 2024 | 25454 | 0.420 |
Why?
| Diabetes Mellitus | 1 | 2015 | 279 | 0.400 |
Why?
| Podocytes | 4 | 2014 | 19 | 0.400 |
Why?
| Angiotensin II | 4 | 2021 | 162 | 0.390 |
Why?
| Nephrology | 2 | 2022 | 11 | 0.350 |
Why?
| Azotemia | 1 | 2010 | 2 | 0.350 |
Why?
| Kidney Tubular Necrosis, Acute | 1 | 2010 | 8 | 0.350 |
Why?
| Inappropriate ADH Syndrome | 1 | 2010 | 2 | 0.350 |
Why?
| Thrombosis | 2 | 2023 | 249 | 0.340 |
Why?
| Angiotensinogen | 3 | 2013 | 12 | 0.330 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 10 | 2013 | 63 | 0.330 |
Why?
| Creatinine | 6 | 2018 | 140 | 0.320 |
Why?
| Sodium | 3 | 2015 | 92 | 0.320 |
Why?
| Angiotensin I | 4 | 2014 | 14 | 0.320 |
Why?
| Female | 22 | 2024 | 26576 | 0.320 |
Why?
| Peptidyl-Dipeptidase A | 3 | 2021 | 27 | 0.310 |
Why?
| Middle Aged | 16 | 2024 | 12293 | 0.290 |
Why?
| Reproducibility of Results | 5 | 2010 | 1182 | 0.290 |
Why?
| Rats, Sprague-Dawley | 7 | 2019 | 1578 | 0.290 |
Why?
| Kidney Cortex | 2 | 2006 | 22 | 0.280 |
Why?
| Mass Spectrometry | 8 | 2023 | 283 | 0.280 |
Why?
| Myocardium | 2 | 2006 | 443 | 0.270 |
Why?
| Aged | 13 | 2024 | 9449 | 0.270 |
Why?
| Urine | 2 | 2003 | 23 | 0.270 |
Why?
| Sea Lions | 2 | 2015 | 2 | 0.260 |
Why?
| Immunoglobulin G | 3 | 2023 | 184 | 0.250 |
Why?
| Kainic Acid | 2 | 2015 | 29 | 0.250 |
Why?
| Severity of Illness Index | 5 | 2015 | 953 | 0.240 |
Why?
| Vitamin D-Binding Protein | 1 | 2024 | 9 | 0.240 |
Why?
| Complement C3 | 1 | 2024 | 20 | 0.240 |
Why?
| Aged, 80 and over | 6 | 2015 | 3138 | 0.240 |
Why?
| Furosemide | 2 | 2015 | 11 | 0.230 |
Why?
| Diuretics | 2 | 2015 | 28 | 0.230 |
Why?
| Peptide Fragments | 4 | 2014 | 207 | 0.230 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2004 | 326 | 0.220 |
Why?
| Kidney Medulla | 1 | 2002 | 16 | 0.210 |
Why?
| Glutamyl Aminopeptidase | 4 | 2017 | 4 | 0.210 |
Why?
| Models, Biological | 3 | 2016 | 719 | 0.200 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2022 | 19 | 0.200 |
Why?
| Urinalysis | 2 | 2013 | 32 | 0.200 |
Why?
| Antibodies, Neutralizing | 1 | 2022 | 62 | 0.190 |
Why?
| Medicine | 1 | 2022 | 56 | 0.190 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2021 | 57 | 0.190 |
Why?
| Blood Platelets | 1 | 2023 | 249 | 0.190 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2020 | 68 | 0.170 |
Why?
| Students, Medical | 1 | 2022 | 159 | 0.170 |
Why?
| Adult | 10 | 2019 | 13356 | 0.170 |
Why?
| Vaccination | 1 | 2022 | 275 | 0.170 |
Why?
| Clinical Competence | 2 | 2024 | 396 | 0.170 |
Why?
| Kidney Tubules, Collecting | 2 | 2011 | 9 | 0.160 |
Why?
| Sphingolipids | 1 | 2019 | 15 | 0.160 |
Why?
| Permeability | 1 | 2019 | 68 | 0.160 |
Why?
| Internship and Residency | 1 | 2024 | 442 | 0.160 |
Why?
| Membrane Proteins | 2 | 2023 | 347 | 0.150 |
Why?
| Algorithms | 3 | 2016 | 613 | 0.150 |
Why?
| Intestinal Mucosa | 1 | 2019 | 215 | 0.150 |
Why?
| Vancomycin | 1 | 2018 | 80 | 0.150 |
Why?
| Host-Pathogen Interactions | 1 | 2019 | 136 | 0.150 |
Why?
| User-Computer Interface | 3 | 2008 | 81 | 0.150 |
Why?
| Mesangial Cells | 2 | 2015 | 4 | 0.150 |
Why?
| Cryopreservation | 1 | 2017 | 31 | 0.140 |
Why?
| Mice | 9 | 2024 | 5658 | 0.140 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 234 | 0.140 |
Why?
| Receptors, Virus | 2 | 2015 | 24 | 0.140 |
Why?
| Mitochondrial Proteins | 1 | 2017 | 88 | 0.140 |
Why?
| Chromatography, Liquid | 3 | 2013 | 225 | 0.140 |
Why?
| Area Under Curve | 2 | 2013 | 178 | 0.130 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2019 | 201 | 0.130 |
Why?
| Database Management Systems | 2 | 2008 | 28 | 0.130 |
Why?
| Heart Ventricles | 2 | 2010 | 252 | 0.130 |
Why?
| Blood Urea Nitrogen | 2 | 2020 | 40 | 0.130 |
Why?
| ROC Curve | 2 | 2013 | 225 | 0.130 |
Why?
| South Carolina | 1 | 2015 | 21 | 0.130 |
Why?
| Kidney Function Tests | 1 | 2015 | 49 | 0.130 |
Why?
| Renin | 2 | 2013 | 19 | 0.130 |
Why?
| Kidney Transplantation | 1 | 2017 | 175 | 0.130 |
Why?
| Glycosphingolipids | 1 | 2015 | 3 | 0.130 |
Why?
| Neuromuscular Depolarizing Agents | 1 | 2015 | 3 | 0.130 |
Why?
| Mitochondrial Proton-Translocating ATPases | 1 | 2015 | 4 | 0.120 |
Why?
| Dietary Supplements | 1 | 2019 | 437 | 0.120 |
Why?
| Diabetes Mellitus, Experimental | 2 | 2015 | 129 | 0.120 |
Why?
| Peptide Mapping | 3 | 2003 | 22 | 0.120 |
Why?
| Apolipoproteins E | 1 | 2015 | 55 | 0.120 |
Why?
| Regression Analysis | 1 | 2015 | 385 | 0.120 |
Why?
| Neurodegenerative Diseases | 1 | 2015 | 72 | 0.120 |
Why?
| Risk Factors | 4 | 2021 | 3605 | 0.120 |
Why?
| Platelet Count | 2 | 2024 | 64 | 0.110 |
Why?
| Haptoglobins | 1 | 2013 | 4 | 0.110 |
Why?
| Albuminuria | 3 | 2022 | 46 | 0.110 |
Why?
| Amino Acid Sequence | 3 | 2003 | 579 | 0.110 |
Why?
| Thioredoxins | 1 | 2013 | 25 | 0.110 |
Why?
| Angiotensins | 1 | 2013 | 12 | 0.110 |
Why?
| Molecular Sequence Data | 3 | 2003 | 799 | 0.110 |
Why?
| Exercise Test | 1 | 2013 | 129 | 0.110 |
Why?
| Infusions, Intravenous | 2 | 2011 | 212 | 0.110 |
Why?
| Radiation-Protective Agents | 1 | 2013 | 72 | 0.110 |
Why?
| Suramin | 1 | 2012 | 13 | 0.100 |
Why?
| Metabolic Networks and Pathways | 1 | 2013 | 90 | 0.100 |
Why?
| Time Factors | 3 | 2013 | 2891 | 0.100 |
Why?
| Anti-Bacterial Agents | 1 | 2018 | 742 | 0.100 |
Why?
| Blotting, Western | 3 | 2017 | 587 | 0.100 |
Why?
| Receptors, Phospholipase A2 | 2 | 2023 | 14 | 0.100 |
Why?
| Kidney Tubules, Proximal | 2 | 2015 | 62 | 0.100 |
Why?
| Bone Marrow | 1 | 2013 | 351 | 0.100 |
Why?
| Mitochondria | 1 | 2015 | 395 | 0.100 |
Why?
| Intensive Care Units | 1 | 2013 | 223 | 0.100 |
Why?
| Phosphatidylethanolamine Binding Protein | 1 | 2011 | 1 | 0.090 |
Why?
| Chemistry, Pharmaceutical | 1 | 2011 | 33 | 0.090 |
Why?
| Retrospective Studies | 4 | 2015 | 6124 | 0.090 |
Why?
| Platelet Aggregation Inhibitors | 2 | 2023 | 174 | 0.090 |
Why?
| Neprilysin | 4 | 2013 | 14 | 0.090 |
Why?
| Mechanotransduction, Cellular | 1 | 2011 | 36 | 0.090 |
Why?
| Nephrosis, Lipoid | 1 | 2010 | 5 | 0.090 |
Why?
| Retinol-Binding Proteins, Plasma | 1 | 2010 | 3 | 0.090 |
Why?
| Neoplasms | 1 | 2020 | 1234 | 0.090 |
Why?
| Endothelial Cells | 1 | 2012 | 256 | 0.090 |
Why?
| Serum Albumin | 1 | 2010 | 58 | 0.090 |
Why?
| Epithelial Cells | 1 | 2011 | 209 | 0.080 |
Why?
| Burkholderia cepacia complex | 1 | 2008 | 1 | 0.080 |
Why?
| Tropomyosin | 1 | 2008 | 5 | 0.080 |
Why?
| Nickel | 1 | 2008 | 11 | 0.080 |
Why?
| Risk Assessment | 1 | 2013 | 1255 | 0.080 |
Why?
| Vimentin | 1 | 2008 | 32 | 0.080 |
Why?
| Lamin Type A | 1 | 2008 | 6 | 0.080 |
Why?
| Proto-Oncogene Proteins | 2 | 2015 | 155 | 0.080 |
Why?
| Inflammation | 2 | 2023 | 603 | 0.080 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 555 | 0.080 |
Why?
| Information Storage and Retrieval | 2 | 2008 | 61 | 0.080 |
Why?
| Cell Line | 4 | 2015 | 1010 | 0.080 |
Why?
| Protein Array Analysis | 2 | 2008 | 23 | 0.080 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2008 | 189 | 0.070 |
Why?
| Models, Theoretical | 2 | 2005 | 172 | 0.070 |
Why?
| Nephrolithiasis | 1 | 2006 | 2 | 0.070 |
Why?
| Loop of Henle | 1 | 2006 | 8 | 0.070 |
Why?
| Kidney Tubules, Distal | 1 | 2006 | 14 | 0.070 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2013 | 483 | 0.070 |
Why?
| Cluster Analysis | 1 | 2007 | 233 | 0.070 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1037 | 0.070 |
Why?
| Internet | 2 | 2008 | 261 | 0.070 |
Why?
| Diagnostic Techniques, Urological | 1 | 2005 | 1 | 0.070 |
Why?
| United States | 2 | 2013 | 4883 | 0.070 |
Why?
| Treatment Outcome | 4 | 2023 | 5178 | 0.060 |
Why?
| Hospitalization | 1 | 2010 | 663 | 0.060 |
Why?
| Chick Embryo | 1 | 2005 | 83 | 0.060 |
Why?
| Renal Dialysis | 1 | 2006 | 170 | 0.060 |
Why?
| Kidney Neoplasms | 1 | 2006 | 172 | 0.060 |
Why?
| Dialysis Solutions | 1 | 2004 | 3 | 0.060 |
Why?
| Databases, Protein | 1 | 2005 | 28 | 0.060 |
Why?
| Hemofiltration | 1 | 2004 | 7 | 0.060 |
Why?
| Protein Biosynthesis | 1 | 2006 | 252 | 0.060 |
Why?
| Feedback | 1 | 2024 | 52 | 0.060 |
Why?
| Accreditation | 1 | 2024 | 60 | 0.060 |
Why?
| Terminology as Topic | 1 | 2004 | 63 | 0.050 |
Why?
| Antigen-Antibody Complex | 1 | 2023 | 35 | 0.050 |
Why?
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2002 | 5 | 0.050 |
Why?
| Receptors, Adrenergic, beta-2 | 1 | 2002 | 16 | 0.050 |
Why?
| Antibodies | 1 | 2003 | 151 | 0.050 |
Why?
| Platelet Aggregation | 1 | 2023 | 71 | 0.050 |
Why?
| Chi-Square Distribution | 2 | 2013 | 275 | 0.050 |
Why?
| Adenosine | 1 | 2023 | 70 | 0.050 |
Why?
| Biopsy | 2 | 2018 | 591 | 0.050 |
Why?
| Kallikreins | 1 | 2002 | 18 | 0.050 |
Why?
| Ticlopidine | 1 | 2023 | 55 | 0.050 |
Why?
| Actins | 1 | 2003 | 115 | 0.050 |
Why?
| Apolipoproteins | 1 | 2021 | 11 | 0.050 |
Why?
| Education, Medical, Graduate | 1 | 2024 | 211 | 0.050 |
Why?
| Cohort Studies | 2 | 2018 | 1403 | 0.050 |
Why?
| Protein Processing, Post-Translational | 1 | 2003 | 154 | 0.050 |
Why?
| Glomerular Basement Membrane | 1 | 2021 | 10 | 0.050 |
Why?
| Mice, Knockout | 2 | 2017 | 835 | 0.050 |
Why?
| Receptors, Transforming Growth Factor beta | 1 | 2021 | 25 | 0.050 |
Why?
| Career Choice | 1 | 2022 | 110 | 0.050 |
Why?
| Proteoglycans | 1 | 2021 | 81 | 0.050 |
Why?
| Neural Cell Adhesion Molecules | 1 | 2020 | 9 | 0.050 |
Why?
| Thrombospondins | 1 | 2020 | 8 | 0.050 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2022 | 388 | 0.050 |
Why?
| Disease Models, Animal | 2 | 2020 | 1411 | 0.040 |
Why?
| Calcium-Binding Proteins | 1 | 2020 | 54 | 0.040 |
Why?
| Logistic Models | 2 | 2013 | 896 | 0.040 |
Why?
| Autoantigens | 1 | 2020 | 50 | 0.040 |
Why?
| Genotype | 1 | 2021 | 539 | 0.040 |
Why?
| Case-Control Studies | 1 | 2023 | 1129 | 0.040 |
Why?
| Young Adult | 3 | 2019 | 4031 | 0.040 |
Why?
| Cytokines | 1 | 2022 | 607 | 0.040 |
Why?
| Cell Proliferation | 2 | 2015 | 986 | 0.040 |
Why?
| Glycosylation | 1 | 2019 | 102 | 0.040 |
Why?
| Mice, Inbred C57BL | 2 | 2015 | 1777 | 0.040 |
Why?
| Colorimetry | 1 | 2018 | 11 | 0.040 |
Why?
| Cadaver | 1 | 2018 | 96 | 0.040 |
Why?
| Rats, Inbred Lew | 1 | 2017 | 43 | 0.040 |
Why?
| Manikins | 1 | 2018 | 35 | 0.040 |
Why?
| Postoperative Complications | 1 | 2024 | 1018 | 0.040 |
Why?
| Ultrasonography, Interventional | 1 | 2018 | 137 | 0.030 |
Why?
| Self Efficacy | 1 | 2018 | 130 | 0.030 |
Why?
| Disease Susceptibility | 1 | 2017 | 88 | 0.030 |
Why?
| Fellowships and Scholarships | 1 | 2018 | 118 | 0.030 |
Why?
| Cells, Cultured | 2 | 2012 | 1587 | 0.030 |
Why?
| Antibody Specificity | 1 | 2015 | 35 | 0.030 |
Why?
| Information Dissemination | 2 | 2008 | 79 | 0.030 |
Why?
| Lactosylceramides | 1 | 2015 | 2 | 0.030 |
Why?
| Cross Reactions | 1 | 2015 | 41 | 0.030 |
Why?
| Albumins | 1 | 2015 | 30 | 0.030 |
Why?
| Oncogene Protein v-akt | 1 | 2015 | 10 | 0.030 |
Why?
| Smad3 Protein | 1 | 2015 | 9 | 0.030 |
Why?
| Uromodulin | 1 | 2015 | 4 | 0.030 |
Why?
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2015 | 12 | 0.030 |
Why?
| Insulin-Like Growth Factor Binding Proteins | 1 | 2015 | 29 | 0.030 |
Why?
| Lipocalins | 1 | 2015 | 13 | 0.030 |
Why?
| Child | 2 | 2022 | 6849 | 0.030 |
Why?
| Acute-Phase Proteins | 1 | 2015 | 24 | 0.030 |
Why?
| Eosinophils | 1 | 2015 | 43 | 0.030 |
Why?
| Radioligand Assay | 1 | 2014 | 46 | 0.030 |
Why?
| Neurotoxicity Syndromes | 1 | 2015 | 46 | 0.030 |
Why?
| Injections, Intravenous | 1 | 2014 | 135 | 0.030 |
Why?
| Feasibility Studies | 1 | 2016 | 382 | 0.030 |
Why?
| Treatment Failure | 1 | 2014 | 116 | 0.030 |
Why?
| Nephrectomy | 1 | 2014 | 81 | 0.030 |
Why?
| HEK293 Cells | 1 | 2014 | 216 | 0.030 |
Why?
| Antigens, CD | 1 | 2015 | 215 | 0.030 |
Why?
| Drug Administration Schedule | 1 | 2014 | 369 | 0.030 |
Why?
| Mice, Congenic | 1 | 2013 | 7 | 0.030 |
Why?
| Adolescent | 2 | 2019 | 6417 | 0.030 |
Why?
| Colony-Forming Units Assay | 1 | 2013 | 23 | 0.030 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 488 | 0.030 |
Why?
| Extracellular Fluid | 1 | 2013 | 14 | 0.030 |
Why?
| Stem Cell Niche | 1 | 2013 | 9 | 0.030 |
Why?
| Benzylamines | 1 | 2013 | 15 | 0.030 |
Why?
| Heterocyclic Compounds | 1 | 2013 | 29 | 0.030 |
Why?
| Cellular Microenvironment | 1 | 2013 | 27 | 0.030 |
Why?
| Hematopoiesis | 1 | 2013 | 70 | 0.030 |
Why?
| Systems Biology | 1 | 2013 | 33 | 0.030 |
Why?
| Bone Marrow Cells | 1 | 2013 | 190 | 0.030 |
Why?
| Bayes Theorem | 1 | 2013 | 105 | 0.030 |
Why?
| Carboxypeptidases | 1 | 2012 | 4 | 0.030 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2012 | 61 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2013 | 463 | 0.020 |
Why?
| Transforming Growth Factor beta1 | 1 | 2012 | 60 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2013 | 579 | 0.020 |
Why?
| Hematopoietic Stem Cells | 1 | 2013 | 182 | 0.020 |
Why?
| Risk | 1 | 2012 | 314 | 0.020 |
Why?
| Up-Regulation | 1 | 2013 | 446 | 0.020 |
Why?
| Random Allocation | 1 | 2012 | 285 | 0.020 |
Why?
| Computational Biology | 2 | 2004 | 214 | 0.020 |
Why?
| Odds Ratio | 1 | 2013 | 548 | 0.020 |
Why?
| Cilia | 1 | 2011 | 6 | 0.020 |
Why?
| Hospital Mortality | 1 | 2013 | 409 | 0.020 |
Why?
| Rotation | 1 | 2011 | 44 | 0.020 |
Why?
| Pilot Projects | 1 | 2013 | 702 | 0.020 |
Why?
| Blood Volume | 1 | 2011 | 69 | 0.020 |
Why?
| Protein Kinase C | 1 | 2011 | 70 | 0.020 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 81 | 0.020 |
Why?
| NF-kappa B | 1 | 2012 | 315 | 0.020 |
Why?
| Urinary Tract | 1 | 2010 | 26 | 0.020 |
Why?
| Tumor Suppressor Proteins | 1 | 2011 | 127 | 0.020 |
Why?
| Kidney Failure, Chronic | 1 | 2012 | 198 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2013 | 1354 | 0.020 |
Why?
| Remission Induction | 1 | 2010 | 205 | 0.020 |
Why?
| Analysis of Variance | 1 | 2011 | 552 | 0.020 |
Why?
| Phosphorylation | 1 | 2011 | 526 | 0.020 |
Why?
| Mice, Transgenic | 1 | 2011 | 543 | 0.020 |
Why?
| Protein Kinase Inhibitors | 1 | 2011 | 205 | 0.020 |
Why?
| Isoantibodies | 1 | 2008 | 27 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 1 | 2008 | 168 | 0.020 |
Why?
| Protein Isoforms | 1 | 2008 | 118 | 0.020 |
Why?
| Recurrence | 1 | 2010 | 658 | 0.020 |
Why?
| Signal Transduction | 1 | 2015 | 1608 | 0.020 |
Why?
| Rats, Wistar | 1 | 2008 | 221 | 0.020 |
Why?
| Hypermedia | 1 | 2008 | 1 | 0.020 |
Why?
| Knowledge Bases | 1 | 2008 | 9 | 0.020 |
Why?
| Cell Differentiation | 1 | 2011 | 649 | 0.020 |
Why?
| Prospective Studies | 1 | 2013 | 2345 | 0.020 |
Why?
| Reference Values | 1 | 2008 | 302 | 0.020 |
Why?
| Protease Inhibitors | 1 | 2007 | 58 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2011 | 2177 | 0.020 |
Why?
| Research Design | 1 | 2008 | 344 | 0.020 |
Why?
| Programming Languages | 1 | 2004 | 6 | 0.010 |
Why?
| Computer Graphics | 1 | 2004 | 9 | 0.010 |
Why?
| Reference Standards | 1 | 2004 | 52 | 0.010 |
Why?
| GTP-Binding Protein alpha Subunit, Gi2 | 1 | 2002 | 3 | 0.010 |
Why?
| Spodoptera | 1 | 2002 | 5 | 0.010 |
Why?
| Receptors, Formyl Peptide | 1 | 2002 | 4 | 0.010 |
Why?
| Receptors, Peptide | 1 | 2002 | 12 | 0.010 |
Why?
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2002 | 15 | 0.010 |
Why?
| Chemical Precipitation | 1 | 2002 | 3 | 0.010 |
Why?
| Tryptases | 1 | 2002 | 4 | 0.010 |
Why?
| Ultracentrifugation | 1 | 2002 | 9 | 0.010 |
Why?
| Acetone | 1 | 2002 | 7 | 0.010 |
Why?
| Isoproterenol | 1 | 2002 | 56 | 0.010 |
Why?
| Solvents | 1 | 2002 | 29 | 0.010 |
Why?
| Receptors, Immunologic | 1 | 2002 | 37 | 0.010 |
Why?
| Staining and Labeling | 1 | 2002 | 97 | 0.010 |
Why?
| Serine Endopeptidases | 1 | 2002 | 51 | 0.010 |
Why?
| Enzyme Activation | 1 | 2002 | 272 | 0.010 |
Why?
| Recombinant Fusion Proteins | 1 | 2002 | 186 | 0.010 |
Why?
| Software | 1 | 2004 | 273 | 0.010 |
Why?
| Child, Preschool | 1 | 2010 | 3879 | 0.010 |
Why?
| Gene Expression Profiling | 1 | 2005 | 1028 | 0.010 |
Why?
| Blood Pressure | 1 | 2002 | 519 | 0.010 |
Why?
|
|
Arthur's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|